Anzeige
Mehr »
Donnerstag, 03.07.2025 - Börsentäglich über 12.000 News
Nach dem Genius Act: Dieses börsennotierte XRP-Unternehmen greift im Token-Finanzmarkt an!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
32 Leser
Artikel bewerten:
(0)

Erectile Dysfunction Drugs Market to Touch US$ 2.87 Billion by 2026; Introduction of Generic Substitutes to Support the Market, Says TMR

ALBANY, New York, December 13, 2018 /PRNewswire/ --

According to TMR analysts, the global erectile dysfunction drugs market is likely to decline at a 3.2% CAGR over the forecast period 2018 to 2026. The market was estimated to be worth US$4.35 Bn in 2016 and is prognosticated to reach a value of US$ 2.87 Bn by 2026.

(Logo: https://mma.prnewswire.com/media/664869/Transparency_Market_Research_Logo.jpg )

Based on the product, Viagra segment led the global erectile dysfunction drugs market until the beginning of the forecast period. The expiry of the patent dealt a severe blow to the segment's dominance, and this trend is expected to affect the business in the coming years.

Geography-wise, North America dominated the overall market owing to higher awareness and availability of branded formulations.

Get PDF Brochure for Research Insights at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1550

Improved Distribution Channels to Boost Growth

With retail pharmacies witnessing a revolution in their processes, management, and size, the global market for erectile dysfunction drugs is likely to be spurred. Retail pharmacies are now getting bigger and better with efficient software, skilled workers, and high competition. Chains of retail pharmacies offering drugs at competitive costs are luring in consumers. This boom in retail pharmacy chains is expected to bode well for the global erectile dysfunction market over the forecast period.

Request a Sample of Report athttps://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1550

Entry of Generic Drugs to Emerge as Leading Market Trend

Viagra, the most popular drug for erectile dysfunction, will go off patent in 2020. This is expected to cause a severe downfall in the global market. However, vendors are now endorsing generic drugs for the same. In 2013, Teva Pharmaceuticals, leading generic drug manufacturer, entered into a settlement with Pzifer for production of the generic version of Viagra.

Request For Discount On This Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1550

Additionally, the generic medicines for Cialis and Levitra, are expected to be boost the global erectile dysfunction drugs market over the coming years. These drugs are expected to be cost efficient, leading to higher acceptance by users.

The global erectile dysfunction drugs market features a highly consolidated vendor landscape, as reported by Transparency Market Research (TMR). The market is expected to see a decline over the coming years on account of loss of patent exclusivity. There exist a few leading manufacturers who currently hold substantial shares in the global market. Due to high unmet needs of the consumers, vendors are expected to focus primarily on research on development of quality products. The manufacture of drugs with little or side-effects, and with improved results, is expected to be a key focus are for vendors in the global erectile dysfunction drugs market.

Browse Press Release - https://www.transparencymarketresearch.com/pressrelease/erectile-dysfunction-drugs.htm

Vendors are also seen adopting other organic and inorganic methods to gain momentum in the international market. Strategies such as mergers and acquisitions, geographical expansion, and collaborations will be adopted by market players to leverage the industry potential.

The top vendors operating in the global erectile dysfunction drugs market are Bayer AG, Pzifer Inc., VIVUS Inc., Eli Lilly and Company, and Dong-A ST Co., Ltd. These players are also involved in the launch of novel products in the coming years.

Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1550

The study presented here is based on a report by Transparency Market Research (TMR) titled, "Erectile Dysfunction (ED) Drugs Market (Drug - Viagra, Cialis, Staxyn/Levitra, Stendra/Spedra; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026."

Popular Research Reports by TMR:

  • Shock Wave Therapy Device Market:

https://www.transparencymarketresearch.com/shock-wave-therapy-device-market.html

  • Drugs of Abuse Testing Market:

https://www.transparencymarketresearch.com/drugs-of-abuse-testing-market-2018-2026.html

  • Active Pharmaceutical Ingredients (API) Market:

https://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR's data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Research Blog: https://theglobalhealthnews.com/


© 2018 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.